Tesamorelin: GHRH Analogue for Visceral Fat Research

Tesamorelin is a synthetic analogue of human growth hormone releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with the addition of a trans-3-hexenoic acid moiety at the N-terminus. This lipophilic modification protects the peptide from DPP-IV (dipeptidyl peptidase-4) enzymatic degradation at the Tyr1-Ala2 site, extending its biological half-life and improving bioavailability compared to native GHRH or truncated analogues like Sermorelin.

Developed by Theratechnologies Inc. of Montreal, Canada, Tesamorelin was FDA-approved in 2010 under the trade name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — a metabolic condition characterised by abnormal fat redistribution, particularly visceral adipose tissue (VAT) accumulation. It remains the only GHRH analogue currently approved by the FDA for any indication.

Tesamorelin's approval for HIV-associated lipodystrophy validated the concept that GHRH-stimulated endogenous GH release can selectively reduce visceral fat without the adverse effects associated with exogenous GH administration. The compound stimulates pituitary GH production through the GHRH receptor while preserving physiological feedback regulation, producing a more targeted and safer metabolic profile.

Beyond its approved indication, Tesamorelin has generated significant research interest for age-related visceral adiposity, cognitive function, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome — conditions where visceral fat accumulation drives pathological outcomes.

Tesamorelin activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs through the same mechanism as endogenous GHRH: Gs-mediated adenylyl cyclase activation, cAMP elevation, and PKA-dependent GH synthesis and secretion. The downstream effects are identical to physiological GHRH signalling — pulsatile GH release, IGF-1 elevation, and preservation of somatostatin-mediated negative feedback.

The trans-3-hexenoic acid modification at the N-terminus provides Tesamorelin's pharmacokinetic advantage over native GHRH. DPP-IV, the enzyme that rapidly cleaves native GHRH between Tyr1 and Ala2 (producing inactive GHRH 3-44), is unable to access the cleavage site due to steric hindrance from the hexenoic acid group. This extends Tesamorelin's half-life to approximately 26-38 minutes — significantly longer than native GHRH (~7 minutes) or Sermorelin (~10-20 minutes).

The extended half-life produces a more sustained GH secretory response following each injection. Clinical pharmacokinetic studies show peak GH levels approximately 30-60 minutes post-injection, with elevated GH persisting for 2-4 hours. IGF-1 levels increase progressively over the first 2-4 weeks of daily Tesamorelin administration, reaching steady state by week 4-6.

Importantly, Tesamorelin does not override somatostatin-mediated feedback, meaning GH levels cannot be elevated beyond physiological capacity. This safety feature — shared with all GHRH analogues but absent with exogenous GH — prevents the supraphysiological GH levels that cause fluid retention, insulin resistance, and other GH-excess side effects.

Tesamorelin's clinical evidence for visceral fat reduction is among the strongest for any peptide compound, underpinned by multiple randomised, placebo-controlled trials that led to FDA approval.

The pivotal Phase 3 trials (Study TH9507-CTR-1015 and TH9507-CTR-1016) enrolled over 800 HIV-infected patients with lipodystrophy and excess abdominal fat. Daily subcutaneous Tesamorelin (2 mg) for 26 weeks produced a mean 15.2% reduction in visceral adipose tissue (measured by CT scan) compared to a 5% increase in the placebo group. This VAT reduction was statistically and clinically significant.

The extension study demonstrated that continued Tesamorelin treatment maintained VAT reduction through 52 weeks, while discontinuation led to VAT rebound, indicating that sustained GHRH-axis stimulation is necessary for ongoing fat reduction. This observation has implications for protocol design in research settings.

Beyond VAT reduction, Tesamorelin treatment improved lipid profiles — reducing trunk fat and triglycerides while increasing adiponectin levels. The compound did not worsen glucose metabolism in the overall study population, though a subgroup of patients with pre-existing glucose impairment showed some increase in fasting glucose, warranting monitoring in metabolic research protocols.

Research outside the HIV population has explored Tesamorelin for age-related visceral adiposity and metabolic syndrome. A landmark study in non-HIV adults demonstrated significant VAT reduction and improved cardiometabolic markers, supporting broader applications. Buy Tesamorelin research vials from Peptides Pharma for metabolic and body composition research with >99% purity.

- Full Name: Tesamorelin acetate / Egrifta - Structure: trans-3-hexenoic acid–GHRH(1-44)NH2 - Molecular Weight: ~5,135.9 g/mol - Classification: Synthetic modified GHRH analogue (full-length, N-terminal protected) - Modification: trans-3-hexenoic acid at N-terminus (DPP-IV protection) - Receptor: GHRH-R (class B GPCR) - Half-life: ~26-38 minutes - FDA Status: Approved (Egrifta) for HIV lipodystrophy (2010) - Developer: Theratechnologies Inc., Montreal

Tesamorelin is the longest peptide in the GHRH analogue class (44 amino acids plus the hexenoic acid cap), which contributes to its higher manufacturing cost compared to shorter analogues like Sermorelin (29 amino acids) or CJC-1295 (29 amino acids with substitutions).

Peptides Pharma Tesamorelin vials are manufactured to >99% HPLC purity in GMP-certified facilities. Full Certificate of Analysis with mass spectrometry verification of molecular weight and purity is included with every order.

Tesamorelin research has expanded beyond body composition into cognitive neuroscience and hepatology, revealing unexpected benefits of GHRH-axis stimulation.

Cognitive Function: A randomised controlled trial published in the Archives of Neurology demonstrated that 20 weeks of Tesamorelin treatment improved cognitive function in healthy older adults and those with mild cognitive impairment (MCI). Executive function and verbal memory scores improved significantly in the Tesamorelin group. The mechanism is attributed to IGF-1-mediated neurotrophic effects, as IGF-1 crosses the blood-brain barrier and supports neuronal survival, synaptic plasticity, and neurogenesis.

Non-Alcoholic Fatty Liver Disease (NAFLD): Research in HIV-infected patients with NAFLD demonstrated that Tesamorelin significantly reduced hepatic fat content (measured by MR spectroscopy), reduced liver fibrosis markers, and improved histological assessments. A Phase 3 trial (PROMISE) confirmed these findings, showing that daily Tesamorelin reduced liver fat by 37% compared to 10% with placebo over 12 months. This hepatic benefit may be mediated by both direct GH effects on hepatic lipid metabolism and indirect effects through visceral fat reduction.

Cardiovascular Risk: VAT accumulation is a driver of cardiovascular disease through inflammatory cytokine production, insulin resistance, and dyslipidaemia. By selectively reducing VAT, Tesamorelin may modify cardiovascular risk factors — a hypothesis supported by improvements in triglycerides, adiponectin, and inflammatory markers observed in clinical trials.

These emerging research applications position Tesamorelin as a multi-system compound relevant to aging, metabolic, cognitive, and hepatic research domains.

The FDA-approved Tesamorelin dose for HIV lipodystrophy is 2 mg administered subcutaneously once daily, and this dose serves as the reference for most research protocols. The injection is typically given in the abdomen, rotating injection sites to prevent lipoatrophy at the administration location.

Research protocols for visceral fat reduction generally run 26-52 weeks based on the clinical trial designs that demonstrated significant VAT changes. Shorter protocols (8-12 weeks) may be sufficient for IGF-1 response characterisation and metabolic marker assessment, as IGF-1 reaches steady state within 4-6 weeks.

For cognitive research, the published trial used the standard 2 mg daily dose for 20 weeks with cognitive testing at baseline and endpoint. Researchers investigating neurocognitive effects should include validated cognitive assessment batteries (MoCA, Trail Making, Verbal Recall) as primary endpoints.

Tesamorelin can be combined with GH secretagogues (ipamorelin, GHRP-6) for enhanced GH-axis stimulation, though the addition of secretagogues to an already robust GHRH analogue like Tesamorelin produces more modest synergy than the combination of Sermorelin with secretagogues, where the shorter GHRH analogue half-life leaves more room for amplification.

Peptides Pharma offers Tesamorelin alongside Sermorelin, CJC-1295, and ipamorelin for comprehensive GH-axis research. All compounds are manufactured to >99% purity with full COA documentation. Buy Tesamorelin UK and worldwide from Peptides Pharma with cold-chain delivery.